Business Wire

TX-DENTALMONITORING

1.6.2021 12:17:11 CEST | Business Wire | Press release

Share
DentalMonitoring Continues to Disrupt the Orthodontic Market With AI-powered Solutions for Braces and Aligners of All Brands

The company that pioneered the field of virtual orthodontics and has been the market leader since 2014 is revolutionizing the industry once again with the only available AI-based virtual monitoring solution applicable to both aligner and braces treatments of all types and brands.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210601005494/en/

In an industry where a vast majority of practices are mixed users, the DentalMonitoring’s solution now allows dental professionals — whether in private practices or DSOs — to take full control of not only their aligner and but also all their braces cases. As a result DentalMonitoring expands its addressable market by close to 75%, helping more practices scale up their business, become more efficient and deliver an outstanding patient experience.

“Our solution has made yet another major breakthrough, and we are proud to unveil a new suite of functionalities of our platform,” says Philippe Salah, CEO of DentalMonitoring. “Dental professionals can now monitor all their aligner and braces cases independent of brand with the same, highly scalable AI-driven workflow. In addition to monitoring treatment progress, they can now actively define and monitor clinical goals for each patient. This results in more active control, productivity and a new level of safety and confidence for their practice: a real mindset shift for our industry.”

Salah continues: “Doctors now have complete control over all orthodontic treatment and can automatically track inter arch parameters such as the overbite, the overjet, the transverse or class correction of patients or detect the archwire and auxiliaries passivity in addition to the intra arch parameters they were already able to track with our solution. Dental professionals can virtualize and automate all non-clinical procedures and schedule appointments only when needed. At the same time, the patients’ compliance and engagement are improved, thanks to the complete revamping of our highly rated patient app.”

As the demand for remote care technology increases within the dental industry, DentalMonitoring continues to lead the way with its virtual practice solutions designed to engage, convert and monitor patients. Powered by AI and a database of over half a billion patient photographs, the virtual practice solutions are designed to give dental professionals the flexibility and convenience they need to safely address all sorts of orthodontic patient cases and optimize chair time.

About DentalMonitoring:

DentalMonitoring’s promise is to help all dental professionals improve their practice efficiency, optimize orthodontic treatment plans and enhance the patient experience thanks to its virtual practice solutions:

- SmileMate , maximizes lead engagement and patient conversion, with the ability for dental professionals to triage and qualify patients even before they step into the practice.

- DentalMonitoring , its flagship solution, monitors all treatments remotely, from aligners and braces of all brands to retention and hygiene.

DentalMonitoring operates across the United States, Europe and Asia with five offices: in Austin, TX, London, Paris, Hong Kong and Sydney.

To learn more about DentalMonitoring, visit www.dental-monitoring.com

DentalMonitoring, Smilemate and Vision are products designed and manufactured by Dental Monitoring SAS, under the DentalMind® branding for Health Care Professional.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release

Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release

New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release

Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release

Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early

Unpack ’26 sommerrejsetrends: Flere vælger indenlandske rejser, når de tænker mere bevidst over deres rejsevalg21.5.2026 12:35:00 CEST | Pressemeddelelse

Rejsebranchens førende databrevne trendrapport lancerer sin første sommerudgave nogensinde – Unpack ’26 Summer: The Trends in Travel I dag har Hotels.com udgivet Unpack ’26 Summer: The Trends in Travel, den nyeste udgave af virksomhedens førende trendrapport i rejsebranchen, som viser, hvordan rejseadfærd former sommerens rejsevalg. Efterspørgslen på indenlandske rejser præger sommerens ferieplanlægning. Interessen på sociale medier for indenlandske ferier er globalt steget med 77% sammenlignet med sidste år, og 44% af danske rejsende planlægger en indenlandsk rejse denne sommer*. Fra store sportsbegivenheder og koncerter til rejser inspireret af film og tv bygger Unpack ’26 Summer på indsigter fra den årlige hovedrapport Unpack ’26: The Trends in Travel™ for at fremhæve, hvor rejsende tager hen denne sommer. HHver tendens bygger på førstehåndsdata fra Hotels.com® kombineret med indsigter fra rejsende og overvågning af sociale medier. “Denne sommer bliver der stadig rejst – men på nye

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye